HOME >> MEDICINE >> NEWS
NIAID Stops AIDS Study Prematurely Because Drug 'Cocktail' Boosts Survival

dicine and director of the AIDS unit; Dr. David Wohl, research fellow in medicine; and research clinician Janet Groves.

Nationwide, researchers found 63 "disease progression events" -- including AIDS-related illnesses and deaths among patients receiving a combination of ZDV and 3TC, Eron said. Among patients receiving those two drugs and indinavir, they found only 33 such events.

"There were 18 deaths in the double-therapy arm of the study vs. eight deaths in the triple- therapy arm," he said. "No major differences were found in either safety or toxicity between the two treatments, and study medications were well-tolerated."

Indinavir, a protease inhibitor, works by preventing protease enzymes from cutting up proteins needed to form viruses, Eron explained. The envelope, or outer coating, of the virus still develops, but the core cannot, and therefore the resulting virus is not infectious.

Drugs such as ZDV and 3TC work by inhibiting an enzyme called reverse transcriptase. That enzyme enables the virus' genetic material, or RNA, to convert human genetic material known as DNA into more virus.

The Food and Drug Administration approved use of the combined ZDV and 3TC in November 1995, in part because of a national study Eron led and published in the New England Journal of Medicine. Indinavir has been approved for about a year.

"The people who should be thanked and congratulated for this study and others like it are the people who participated in the trials," Eron said. "They not only have done something that will improve their own care, but they have volunteered to do something that will clearly improve the care of many patients afterwards.

"Treatment with the triple-drug therapy is not easy because of the large number of pills patients have to take and the commitment they have to make to stick to the therapy," he said. "They are the real heroes here."

Glaxo-Wellcome Inc. of Research Triangle Park
'"/>

Contact: David Williamson
rdtokids@email.unc.edu
919-962-2091
University of North Carolina at Chapel Hill
25-Feb-1997


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... November 22, 2014 The Sports Conflict ... Roy Baroff to its team of conflict resolution professionals. ... player, coach, and referee. He has over 30 years experience ... beyond. , “I'm very excited to connect with SCI and ... related interests to a program with a complete sports focus,” ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
(Date:11/21/2014)... Nov. 21, 2014 In September 2014, the ... carried out a new product development plan that started ... "limited edition" lab coat , aptly named "Vera ... surgery in the world. The new women,s designer lab ... with a sleek envelope collar, vertical princess and high ...
(Date:11/21/2014)... , Nov. 21, 2014  PTC Therapeutics, Inc. (NASDAQ: ... 2014 Legend of Technology Award for Vision, Innovation, and Leadership ... Chief Executive Officer. This award recognizes an individual who has ... New Jersey for several decades. ... Award," stated Stuart Peltz , Ph.D., CEO of PTC ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
Cached News: